Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line	Gilteritinib (ASP2215; Xospata; gilteritinib fumarate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Forigerimod plus Standard of Care for Systemic Lupus Erythematosus	Forigerimod acitate (Lupuzor. IPP-201101; CEP-33457)	Systemic lupus erythematosus (SLE)	Immunology , Nephrology	2018	View \| Download
Fexapotide Triflutate for Benign Prostatic Hyperplasia	Fexapotide (NX-1207; REC 0482)	Benign prostatic hyperplasia (BPH)	Men's Health	2018	View \| Download
Fedratinib for Myelofibrosis	Fedratinib (SAR302503)	Myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2018	View \| Download
Fedovapagon for nocturia in men with benign prostatic hyperplasia	Fedovapagon (VA-106483)	Nocturia	Men's Health , Urology	2018	View \| Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients	Entrectinib (RXDX-101)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2018	View \| Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer	Entrectinib (RXDX-101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Enasidenib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an Isocitrate Dehydrogenase 2 (IDH2) Mutation	Enasidenib (Idhifa; AG-221; CC-90007)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Emapalumab for Primary Haemophagocytic Lymphohistiocytosis	Emapalumab (NI-0501; Gamifant)	Primary haemophagocytic lymphohistiocytosis (HLH)	Genetic Disorders , Immunology	2018	View \| Download
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Elotuzumab (Empliciti; BMS-901608; HuLuc63) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download